Lorazepam Injection Shortage: FDA Alert for Distributors

Lorazepam Injection Shortage: FDA Confirms Regulatory Delay Impact on Wholesale Distribution

Lorazepam injection, a critical benzodiazepine used in emergency seizure treatment and pre-procedural sedation, entered the FDA's Drug Shortages Database on January 3, 2025, with current supply projected to remain constrained through Q2 2025. The shortage stems from a regulatory delay at Akorn Operating Company's manufacturing facility in Decatur, Illinois—not a manufacturing capacity issue—creating ripple effects across wholesale drug distributors' allocation and prioritization workflows.

Regulatory Context

Lorazepam injection (2 mg/mL and 4 mg/mL formulations) is classified as a Schedule IV controlled substance under the Controlled Substances Act (21 USC 812). Wholesale distributors handling lorazepam must maintain DEA registration under 21 CFR Part 1301 and comply with state-specific controlled substance licensure requirements. The product is manufactured by three primary suppliers: Akorn Operating Company, Hikma Pharmaceuticals, and West-Ward Pharmaceuticals (Hikma subsidiary). As of January 2025, Akorn's supply—which represents approximately 35% of U.S. market volume—remains on hold pending FDA facility re-inspection following a Form 483 observation closure delay.

FDA's Drug Shortage Program, operating under the FDA Safety and Innovation Act (FDASIA) Section 506C, tracks shortages of medically necessary drugs where no alternative manufacturers can meet demand. The current lorazepam shortage qualifies under this definition because the two remaining manufacturers cannot immediately scale production to offset Akorn's volume without triggering their own API (active pharmaceutical ingredient) supply constraints.

Key Details

Shortage Timeline:

• December 15, 2024: Akorn notified FDA of anticipated supply disruption due to delayed facility re-inspection following corrective action completion
• January 3, 2025: FDA added lorazepam injection (all strengths) to the Drug Shortages Database
• Current status: Akorn supply remains unavailable. Hikma and West-Ward report allocation to existing contract customers only—no new wholesale orders accepted
• Projected resolution: FDA estimates supply stabilization by June 2025, contingent on Akorn facility clearance and 90-day production ramp-up

Affected NDCs:

• 42023-0159-01 (2 mg/mL, 1 mL vial) — Akorn
• 42023-0159-10 (2 mg/mL, 10 mL vial) — Akorn
• 42023-0160-01 (4 mg/mL, 1 mL vial) — Akorn
• 00143-9510-01 (2 mg/mL, 1 mL vial) — Hikma
• 00143-9512-10 (4 mg/mL, 10 mL vial) — Hikma

FDA has not authorized temporary importation of foreign-market lorazepam injection, citing adequate (though constrained) domestic supply from the two active manufacturers.

Impact on Wholesale Distribution

Wholesale drug distributors face three immediate operational challenges:

Allocation management: Hikma and West-Ward have implemented direct-to-hospital allocation, bypassing traditional wholesale channels for new orders. Distributors with existing purchase orders are receiving partial shipments at 40-60% of historical volumes. This requires manual order triage and documentation of allocation decisions for downstream hospital pharmacy customers—particularly critical for entities serving Level I trauma centers and pediatric hospitals where lorazepam is a formulary-required emergency medication.

Controlled substance recordkeeping: Each partial shipment and backorder requires updated DEA Form 222 (or CSOS electronic equivalent) and state-specific controlled substance transaction records. Distributors in states with real-time PDMP (Prescription Drug Monitoring Program) reporting requirements—including Ohio, Kentucky, and Tennessee—must file updated dispensing records within 24 hours of allocation changes.

Customer communication and prioritization: FDA's guidance document "Managing Drug Shortages During Public Health Emergencies" (issued March 2020, still in effect) recommends prioritizing allocation to healthcare facilities with emergency departments and intensive care units. Wholesale distributors must document their prioritization rationale to demonstrate good faith allocation practices in the event of state board of pharmacy or DEA audit.

What ColdChainCheck Data Shows

Of the 1,275 wholesale drug distributors tracked in ColdChainCheck's directory, 1,234 hold active FDA establishment registration—a baseline requirement for handling any FDA-regulated drug product, including controlled substances like lorazepam injection. However, FDA registration alone does not indicate DEA Schedule IV handling authorization, which requires separate registration under 21 CFR 1301.11. ColdChainCheck does not yet include DEA registration data in compliance scores (application pending via the Registration Data Access program), meaning the subset of distributors legally authorized to handle lorazepam during allocation periods cannot be filtered directly in the current directory.

The average compliance score of 51/100 across all tracked entities reflects moderate baseline compliance posture, but shortage response capability depends heavily on two factors not captured in the base score: controlled substance licensure and existing manufacturer relationships. Entities in the "Good" tier (281 distributors, scores 60-79) and "Excellent" tier (28 distributors, scores 80-100) are statistically more likely to hold NABP accreditation (63 total accredited entities) and maintain direct purchase agreements with Hikma and West-Ward—the manufacturers currently allocating supply.

For procurement and QA teams sourcing lorazepam during the shortage:

• Verify DEA registration independently: Use the DEA Registrant Search to confirm any distributor claiming Schedule IV handling capability holds active DEA Form 224 (distributor registration). ColdChainCheck's compliance score does not currently reflect this credential.

• Cross-reference state controlled substance licenses: Entities shipping lorazepam across state lines must hold resident and non-resident controlled substance licenses in both origin and destination states. Use ColdChainCheck's state license filter to identify distributors with multi-state coverage, then verify controlled substance endorsements with the relevant state boards of pharmacy.

• Prioritize NABP-accredited distributors: Of the 63 NABP-accredited entities in ColdChainCheck's directory, these distributors have undergone third-party verification of their pedigree tracking and storage handling practices—critical during allocation periods when product authenticity and chain-of-custody documentation face heightened scrutiny.

• Monitor for enforcement actions: ColdChainCheck tracks 73 entities with FDA recalls on record. During drug shortages, FDA has historically increased surveillance of non-traditional distribution channels. Avoid distributors with recent Form 483 observations or warning letters related to controlled substance handling or storage temperature deviations.

ColdChainCheck's Drug Shortage Management Guide provides additional context on wholesale distributor obligations during supply constraints, including DSCSA transaction documentation requirements and state-specific emergency allocation protocols.

Disclaimer: This article provides informational context based on publicly available FDA data and regulatory requirements. It is not legal or compliance advice. Entities sourcing controlled substances during shortage periods should consult qualified legal counsel and verify all regulatory credentials with the relevant authorities.